Sign in to continue reading this article

Not registered? Create an account for free to read full articles on www.cliniciansbrief.com.

To access full articles on www.cliniciansbrief.com, please sign in below.

Busy? Sign in Faster. Sign into www.cliniciansbrief.com with your social media account.

This canine study evaluated the pharmacokinetics of 4 oral long-acting formulations of doxycycline mixed with different proportions of acrylic acid and polymethacrylate-based matrix (DOX1, DOX2, DOX3, and DOX4). A control of 20 mg/kg of doxycycline with no excipients was included.

Therapeutic concentrations were observed for 60 hours after administration of DOX1 and DOX4, for 48 hours after DOX2 and DOX3, and for 24 hours after the control dose. Pharmacokinetic parameters between DOX1 and DOX2 and between DOX3 and DOX4 did not differ significantly; however, parameters for the control treatment differed significantly from all long-acting formulations. These doxycycline formulations may be useful in reducing dosing frequency and, in turn, may improve compliance and decrease costs and adverse effects. However, further safety studies are needed.

References Show
References

Source

Arciniegas Ruiz SM, Gutiérrez Olvera L, Bernad Bernad MJ, Caballero Chacón Sdel C, Vargas Estrada D. Comparative pharmacokinetics of a new oral long-acting formulation of doxycycline hyclate: a canine clinical trial. Eur J Pharm Sci. 2015;80:9-15.

Material from Clinician’s Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.

Up Next